

December 23,2022

Press Release

Company: J-Pharma Co., Ltd.  
Contact: Tomohiro Yuzawa, Director,  
Corporate Management  
Tel: 045-506-1155  
info@j-pharma.com

We are pleased to announce J-Pharma's lead oncology product candidate, Nanvuranlat will feature at the upcoming ASCO Gastrointestinal Cancers Symposium, to be held in San Francisco on 19-21 January 2023.

1 . Presentation Details: Rapid Abstract Session B

2 . Rapid Abstract Session:

- Date/Time: January 20,2023 7:10 -7:15 PST
- Place: Level 3, Ballroom

3 . Poster Session

- Date/Time: January 20,2023 12:00 – 13:30 PST
- Place: Level 1, West Hall

4 . Abstract Number: 494

5 . Abstract Title

Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for patients with pretreated advanced refractory biliary tract cancer (BTC): Primary endpoint results of a randomized, double-blind, placebo-controlled phase 2 study